Clinical stage company Genprex Inc. has added to its therapeutics pipeline by licensing gene therapy technology from the University of Pittsburgh that will be used to treat Type 2 diabetes.

Austin,Texas-based Genprex had previously licensed technology targeting Type 1 diabetes from Pitt, adding to its portfolio of potential treatments for diabetes and cancer.

“Each of these technologies may have the potential to provide long-term efficacy and to change the course of this disease for the millions of patients around the world with diabetes,” Genprex Chief Medical Officer Mark Berger said in a prepared statement.

“Both product candidates are based on the same general gene therapy approach under Genprex’s original license that is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreas.”

Advertise with us

The diabetes technologies licensed from Pitt came from the laboratory of George Gittes, chief of the Division of Pediatric Surgery at UPMC Children’s Hospital of Pittsburgh.

In the 2020 licensing agreement with Pitt, Genprex agreed to pay an initial fee of $25,000, annual maintenance fees of $25,000 for the first three years and $40,000 for each year after the first anniversary of the agreement.

The university will also receive an annual minimal royalty payment of $250,000 with the first commercial sale of the technology and an aggregate payment of $3.9 million for reaching progress milestones.

Genprex is a pre-revenue company that reported a $17 million loss for the nine months ending Sept. 30, compared to a $14 million loss a year ago. As of Sept. 30, the company had an accumulated deficit of $94.9 million and its operations have primarily been funded through the sale and issuance of stock.

Kris B. Mamula: kmamula@post-gazette.com